Effects of endogenous anticancer oestrogen metabolite on biological activity

January 13, 2014, University of Bath
The researchers designed an imaginative cover feature illustrating the drug molecule as a synthesis of discrete fragments, flanked by renderings of the target protein, tubulin. In the background is an image of cultured cells expressing recombinant tagged tubulin, labelled with a green fluorescent dye.

A publication on anti-cancer drug candidates designed by University of Bath researchers in the Department of Pharmacy & Pharmacology has been awarded Very Important Paper status by the medicinal chemistry journal ChemMedChem.

The paper entitled "Tetrahydroisoquinolinone-based Steroidomimetic and Chimeric Microtubule Disruptors" describes how the researchers designed the prototype using fragments derived from 2-methoxyoestradiol (an endogenous anticancer oestrogen metabolite) and colchicine (a compound extracted from a crocus) as templates. They then combined these together in new hybrid structures and modified them systematically to explore the effects on biological activity.

The work was carried out as part of the assets of Sterix Ltd – a University spin-out company with Imperial College – and, more recently, in collaboration with a specialist group in the USA.

Sterix Ltd was co-founded by Professor Barry Potter from our Department of Pharmacy & Pharmacology and was acquired by the pharmaceutical company Ipsen in 2004.

The paper appeared in this month's issue of the journal, which includes a special invited cover feature designed by the researchers.

Professor Potter said: "It is highly rewarding to see the creation of this new drug class from our synthetic laboratory and its high level pre-clinical development. It is also encouraging to see the ongoing academic peer recognition of our work.

"This work emphasises the continuing strength of medicinal chemistry at the University and demonstrates again that academic scientists can play a key role in discovering – traditionally a preserve of the pharmaceutical industry."

Professor Potter also started work as an invited member of the ChemMedChem International Advisory Board at the beginning of January.

Explore further: Cancer drug developed at University of Bath begins trials

More information: "Tetrahydroisoquinolinone-Based Steroidomimetic and Chimeric Microtubule Disruptors." Dr. Mathew P. Leese, Dr. Fabrice L. Jourdan, Dr. Meriel R. Major, et al. ChemMedChem. Volume 9, Issue 1, pages 85–108, January 2014. DOI: 10.1002/cmdc.201300261

Related Stories

Cancer drug developed at University of Bath begins trials

November 7, 2013
Trials are beginning for Irosustat, a drug pioneered here at the University, which could prolong the lives of thousands of women with advanced breast cancer.

3D structure opens new avenue for drug discovery

April 2, 2012
(PhysOrg.com) -- An international consortium has determined the structure of an important new drug target in complex with a synthetic molecule designed by our researchers, opening up new avenues for drug discovery.

New discovery in quest for better drugs

October 14, 2013
Scientists have combined cutting edge computer modelling with pharmacology and medicinal chemistry to reveal new insights into how the body interacts with novel drug treatments, in research that could lead to the creation ...

Why combination drug treatment ineffective in cancer clinical trials

December 5, 2013
Medical researchers at the University of Alberta have discovered that combination drug therapy didn't work well in clinical trials for cancer patients because one drug was making the other drug ineffective.

Recommended for you

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.